Rosetta Genomics Ltd (ROSG) 3.98 $ROSG
Rosetta Genomics wins Notice of Allowance for patent covering the method to identify cancer origin
M2 - Mon Apr 07, 9:39AM CDT
Molecular diagnostics company Rosetta Genomics (NASDAQ:ROSG) reported on Friday the receipt of a Notice of Allowance for a patent covering the method of use of a core element of its microRNA technology in the identification of the tumor of origin in cancer of unknown or uncertain primary and metastatic cancer.
Rosetta Genomics to Receive U.S. Patent for Cancer Origin Assay
Marketwire - Fri Apr 04, 7:16AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent covering the method of use of a core element of Rosetta Genomics' microRNA technology in the identification of the tumor of origin in cancer of unknown or uncertain primary and metastatic cancer. The issued claims for U.S. Patent Application No. 13/167,489 is entitled "Gene Expression Signature for Classification of Tissue of Origin of Tumor Samples."
Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based Diagnostics and Therapeutics for Rare Diseases
Marketwire - Wed Apr 02, 8:09AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced that they had established a strategic alliance, wherein the companies will collaborate to identify and develop microRNA-based products designed to diagnose and treat various neuromuscular diseases and dystrophies.
Rosetta Genomics Reports 2013 Financial Results
Marketwire - Mon Mar 31, 5:05PM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today reported financial results for the year ended December 31, 2013.
5 Stocks Set to Soar on Bullish Earnings
at The Street - Mon Mar 31, 12:19PM CDT
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
Rosetta Genomics to Host Business Update Conference Call on April 1, 2014
Marketwire - Tue Mar 25, 1:50PM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today announced that following the close of the U.S. stock market on Monday, March 31, 2014, the Company will file its Annual Report on Form 20-F for the year ended December 31, 2013 with the U.S. Securities and Exchange Commission ("SEC"
. The Form 20-F will include audited annual consolidated financial statements, as well as additional information regarding the Company. The Form 20-F will be available at www.sec.gov and at www.rosettagenomics.com.
Rosetta Genomics Up 97.7% Since SmarTrend Uptrend Call (ROSG)
Comtex SmarTrend(R) - Mon Mar 24, 9:09AM CDT
SmarTrend identified an Uptrend for Rosetta Genomics (NASDAQ:ROSG) on December 5th, 2013 at $3.02. In approximately 4 months, Rosetta Genomics has returned 97.69% as of today's recent price of $5.97.
Rosetta Genomics Enters Collaboration With Clalit Health Services' Rabin Medical Center for microRNA-Based Assay for Chronic Allograft Dysfunction Following Kidney Transplantation
Marketwire - Mon Mar 24, 8:15AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, reports that the Company has entered a joint collaboration with Clalit Health Services' Rabin Medical Center-Beilinson Campus (Petah Tikvah, Israel), a non-profit corporation, for the development of a non-invasive, microRNA-based, assay for the diagnosis of chronic allograft dysfunction (CAD or chronic rejection) following kidney transplantation.
Rosetta Genomics' Cancer Origin Test Highlighted at Landmark CUP Foundation Seminar 2014
Marketwire - Fri Mar 21, 11:15AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, reports that the Company is sponsoring and participating in the CUP Foundation seminar 2014 taking place from March 21-22 in London, England. This international medical seminar highlights the management, treatment, diagnosis and future perspectives of Cancer of Unknown Primary (CUP) by some of the world's leading clinicians for CUP and is supported by the European Society for Medical Oncology (ESMO) and the European School of Oncology.
Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics
PR Newswire - Thu Mar 13, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Uptrend Call Working As Rosetta Genomics Stock Rises 100.7% (ROSG)
Comtex SmarTrend(R) - Wed Mar 12, 9:07AM CDT
SmarTrend identified an Uptrend for Rosetta Genomics (NASDAQ:ROSG) on December 5th, 2013 at $3.02. In approximately 3 months, Rosetta Genomics has returned 100.66% as of today's recent price of $6.06.
Rosetta Genomics Provides Product Pipeline Update
Marketwire - Wed Mar 12, 7:16AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces details regarding the Company's plans to advance its proprietary microRNA platform technologies in diagnostics and therapeutics.
Shares of Rosetta Genomics Receive a Boost, Up 6.4% - March 05, 2014
Comtex SmarTrend(R) - Wed Mar 05, 9:13AM CST
One of today's stocks on the move is Rosetta Genomics (NASDAQ:ROSG), up 6.4% to $5.48. The Dow Jones Industrial Average is now trading fractionally lower to 16,377 and the S&P is trading fractionally lower to 1,872.
Nasdaq stocks posting largest percentage increases
AP - Tue Mar 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Rosetta Genomics wins Notice of Allowance for patent covering the method to identify cancer origin
M2 - Mon Apr 07, 9:39AM CDT
Molecular diagnostics company Rosetta Genomics (NASDAQ:ROSG) reported on Friday the receipt of a Notice of Allowance for a patent covering the method of use of a core element of its microRNA technology in the identification of the tumor of origin in cancer of unknown or uncertain primary and metastatic cancer.
Rosetta Genomics to Receive U.S. Patent for Cancer Origin Assay
Marketwire - Fri Apr 04, 7:16AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent covering the method of use of a core element of Rosetta Genomics' microRNA technology in the identification of the tumor of origin in cancer of unknown or uncertain primary and metastatic cancer. The issued claims for U.S. Patent Application No. 13/167,489 is entitled "Gene Expression Signature for Classification of Tissue of Origin of Tumor Samples."
Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based Diagnostics and Therapeutics for Rare Diseases
Marketwire - Wed Apr 02, 8:09AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced that they had established a strategic alliance, wherein the companies will collaborate to identify and develop microRNA-based products designed to diagnose and treat various neuromuscular diseases and dystrophies.
Rosetta Genomics Reports 2013 Financial Results
Marketwire - Mon Mar 31, 5:05PM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today reported financial results for the year ended December 31, 2013.
5 Stocks Set to Soar on Bullish Earnings
at The Street - Mon Mar 31, 12:19PM CDT
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
Rosetta Genomics to Host Business Update Conference Call on April 1, 2014
Marketwire - Tue Mar 25, 1:50PM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today announced that following the close of the U.S. stock market on Monday, March 31, 2014, the Company will file its Annual Report on Form 20-F for the year ended December 31, 2013 with the U.S. Securities and Exchange Commission ("SEC"
. The Form 20-F will include audited annual consolidated financial statements, as well as additional information regarding the Company. The Form 20-F will be available at www.sec.gov and at www.rosettagenomics.com. Rosetta Genomics Up 97.7% Since SmarTrend Uptrend Call (ROSG)
Comtex SmarTrend(R) - Mon Mar 24, 9:09AM CDT
SmarTrend identified an Uptrend for Rosetta Genomics (NASDAQ:ROSG) on December 5th, 2013 at $3.02. In approximately 4 months, Rosetta Genomics has returned 97.69% as of today's recent price of $5.97.
Rosetta Genomics Enters Collaboration With Clalit Health Services' Rabin Medical Center for microRNA-Based Assay for Chronic Allograft Dysfunction Following Kidney Transplantation
Marketwire - Mon Mar 24, 8:15AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, reports that the Company has entered a joint collaboration with Clalit Health Services' Rabin Medical Center-Beilinson Campus (Petah Tikvah, Israel), a non-profit corporation, for the development of a non-invasive, microRNA-based, assay for the diagnosis of chronic allograft dysfunction (CAD or chronic rejection) following kidney transplantation.
Rosetta Genomics' Cancer Origin Test Highlighted at Landmark CUP Foundation Seminar 2014
Marketwire - Fri Mar 21, 11:15AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, reports that the Company is sponsoring and participating in the CUP Foundation seminar 2014 taking place from March 21-22 in London, England. This international medical seminar highlights the management, treatment, diagnosis and future perspectives of Cancer of Unknown Primary (CUP) by some of the world's leading clinicians for CUP and is supported by the European Society for Medical Oncology (ESMO) and the European School of Oncology.
Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics
PR Newswire - Thu Mar 13, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Uptrend Call Working As Rosetta Genomics Stock Rises 100.7% (ROSG)
Comtex SmarTrend(R) - Wed Mar 12, 9:07AM CDT
SmarTrend identified an Uptrend for Rosetta Genomics (NASDAQ:ROSG) on December 5th, 2013 at $3.02. In approximately 3 months, Rosetta Genomics has returned 100.66% as of today's recent price of $6.06.
Rosetta Genomics Provides Product Pipeline Update
Marketwire - Wed Mar 12, 7:16AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces details regarding the Company's plans to advance its proprietary microRNA platform technologies in diagnostics and therapeutics.
Shares of Rosetta Genomics Receive a Boost, Up 6.4% - March 05, 2014
Comtex SmarTrend(R) - Wed Mar 05, 9:13AM CST
One of today's stocks on the move is Rosetta Genomics (NASDAQ:ROSG), up 6.4% to $5.48. The Dow Jones Industrial Average is now trading fractionally lower to 16,377 and the S&P is trading fractionally lower to 1,872.
Nasdaq stocks posting largest percentage increases
AP - Tue Mar 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
